ERBB2 and cancer: In the National Cancer Database (2010–2015), among 315,264 patients receiving chemotherapy, triple-negative breast cancer had the highest neoadjuvant chemotherapy rates (increasing from 19.5% to 33.7%), followed by HER2-positive subtypes (HR-/HER2+: 21.5→39.8%; HR+/HER2+: 17.0→33.7%) [4].